Illumina, China

Illumina aims to cut $100M in costs following China import ban
Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue from China, after the country banned the importation of its DN | Illumina also lowered its annual financial forecast,
China hits Illumina with import ban. What does that mean for the San Diego gene sequencer?
China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war
China Bans Imports of Illumina DNA Machines in US Retaliation
China banned the import of Illumina Inc. gene-sequencing machines as part of a wave of retaliatory trade measures in response to the US doubling tariffs on all Chinese goods.
China bans sales of Illumina DNA sequencers as Trump escalates global tariffs
Illumina has been barred from exporting its DNA sequencers to China, which closed | Illumina has been barred from exporting its DNA sequencers to China, which closed its doors to the company in response to the Trump administration expanding its tariffs on the country.
Illumina to cut $100M in costs to cope with China ban
The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.
China bans imports of Illumina's gene sequencers right after Trump tariff action
China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina, just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect.
Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego-based Illumina is lowering its 2025 guidance to $4.
Illumina lowers guidance, cuts spending to mitigate China ban on its gene sequencers
Illumina (NASDAQ:ILMN) on Monday lowered its adjusted profit outlook and cut spending cost for 2025 as the company grapples with Chinese ban on its gene sequencers. Illumina now expects fiscal 2025 non-GAAP diluted EPS of about $4.
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
March 10 (Reuters) - Illumina (ILMN.O), opens new tab on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ...
Illumina’s DNA sequencers hit with China import ban
Illumina is not banned from operating in the country and will continue to serve its existing customers, a company ...
Fierce Pharma7d
Fierce Pharma Asia—Trump's investment policy; Pfizer's tariff mitigation plan; CMIC's stake sale
U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...
Bloomberg L.P.10d
China Bans Illumina Sequencer Imports as Trade Tensions Rise
China banned the import of Illumina Inc. gene-sequencing machines as part of a wave of retaliatory measures against fresh US tariffs on all Chinese goods, deepening the US company’s woes in one ...
Times of San Diego2d
Trade War Fallout Prompts San Diego’s Illumina to Lower Outlook, Cut $100 Million in Costs
Illumina on Monday lowered its annual forecast ... Gene sequencers help determine the sequence of DNA or RNA, allowing scientists to study genetic variations associated with diseases and diagnose ...